Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide

Graham M. Mead, Joyce Thompson, John W. Sweetenham, Roger B. Buchanan, J. Michael A. Whitehouse, Christopher J. Williams

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CAV1, etoposide 500 mg m-2 given in divided dose over days 3-7) on a 21-day schedule. The two regimens proved comparable (CR+PR 55% vs 56%), and the survival curves were virtually superimposable (median survival: CAV1, 8 months; CAV5, 9 months). Only five patients are still alive. The toxicity of the two treatments was similar. The scheduling of etoposide over 1 or 5 days seemed clinically unimportant in this study, perhaps because of concurrent use of other effective chemotherapy drugs.

Original languageEnglish (US)
Pages (from-to)172-174
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1 1987
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Etoposide
Bronchi
Doxorubicin
Cyclophosphamide
Appointments and Schedules
Cells
Chemotherapy
Survival
Toxicity
Scheduling
Drug Therapy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide. / Mead, Graham M.; Thompson, Joyce; Sweetenham, John W.; Buchanan, Roger B.; Whitehouse, J. Michael A.; Williams, Christopher J.

In: Cancer Chemotherapy and Pharmacology, Vol. 19, No. 2, 01.04.1987, p. 172-174.

Research output: Contribution to journalArticle

@article{bece6acdb2b84009a43c45cced96f3be,
title = "Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide",
abstract = "Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CAV1, etoposide 500 mg m-2 given in divided dose over days 3-7) on a 21-day schedule. The two regimens proved comparable (CR+PR 55{\%} vs 56{\%}), and the survival curves were virtually superimposable (median survival: CAV1, 8 months; CAV5, 9 months). Only five patients are still alive. The toxicity of the two treatments was similar. The scheduling of etoposide over 1 or 5 days seemed clinically unimportant in this study, perhaps because of concurrent use of other effective chemotherapy drugs.",
author = "Mead, {Graham M.} and Joyce Thompson and Sweetenham, {John W.} and Buchanan, {Roger B.} and Whitehouse, {J. Michael A.} and Williams, {Christopher J.}",
year = "1987",
month = "4",
day = "1",
doi = "10.1007/BF00254574",
language = "English (US)",
volume = "19",
pages = "172--174",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide

AU - Mead, Graham M.

AU - Thompson, Joyce

AU - Sweetenham, John W.

AU - Buchanan, Roger B.

AU - Whitehouse, J. Michael A.

AU - Williams, Christopher J.

PY - 1987/4/1

Y1 - 1987/4/1

N2 - Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CAV1, etoposide 500 mg m-2 given in divided dose over days 3-7) on a 21-day schedule. The two regimens proved comparable (CR+PR 55% vs 56%), and the survival curves were virtually superimposable (median survival: CAV1, 8 months; CAV5, 9 months). Only five patients are still alive. The toxicity of the two treatments was similar. The scheduling of etoposide over 1 or 5 days seemed clinically unimportant in this study, perhaps because of concurrent use of other effective chemotherapy drugs.

AB - Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CAV1, etoposide 500 mg m-2 given in divided dose over days 3-7) on a 21-day schedule. The two regimens proved comparable (CR+PR 55% vs 56%), and the survival curves were virtually superimposable (median survival: CAV1, 8 months; CAV5, 9 months). Only five patients are still alive. The toxicity of the two treatments was similar. The scheduling of etoposide over 1 or 5 days seemed clinically unimportant in this study, perhaps because of concurrent use of other effective chemotherapy drugs.

UR - http://www.scopus.com/inward/record.url?scp=0023234941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023234941&partnerID=8YFLogxK

U2 - 10.1007/BF00254574

DO - 10.1007/BF00254574

M3 - Article

C2 - 3032470

AN - SCOPUS:0023234941

VL - 19

SP - 172

EP - 174

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -